IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

Core Viewpoint - IceCure Medical Ltd. has announced that Thomas Hospital in Alabama has installed the ProSense® system, making it the first hospital in the state to offer breast cancer cryoablation procedures, which are set to begin in the coming weeks [1]. Group 1: Company Developments - IceCure Medical specializes in minimally-invasive cryoablation technology aimed at destroying tumors through freezing, providing an alternative to surgical tumor removal [1]. - The ProSense® Cryoablation System is the first medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer in women aged 70 and above, including those unsuitable for surgical options [1]. - The installation of ProSense® at Thomas Hospital was funded by the Thomas Hospital Foundation, which aims to support access to advanced medical technology [1]. Group 2: Market Impact - The installation follows increased interest in ProSense® after its FDA clearance in October 2025 for treating low-risk breast cancer, indicating a potential rise in installations across other facilities [1]. - IceCure's Vice President of Sales noted that the hospital network's patient volume could lead to a significant number of eligible women benefiting from the ProSense® system as a minimally invasive treatment option [1]. Group 3: Technology Overview - ProSense® utilizes liquid nitrogen to create large lethal zones for effective tumor destruction in both benign and cancerous lesions, enhancing patient recovery and reducing surgical risks [1]. - The system's design allows for fast and convenient office-based procedures, making it a valuable addition to breast cancer treatment options [1].